Logo image of RPID

RAPID MICRO BIOSYSTEMS INC-A (RPID) Stock Fundamental Analysis

NASDAQ:RPID - Nasdaq - US75340L1044 - Common Stock - Currency: USD

3.33  -0.04 (-1.19%)

After market: 3.33 0 (0%)

Fundamental Rating

2

Overall RPID gets a fundamental rating of 2 out of 10. We evaluated RPID against 55 industry peers in the Life Sciences Tools & Services industry. While RPID seems to be doing ok healthwise, there are quite some concerns on its profitability. RPID is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year RPID has reported negative net income.
RPID had a negative operating cash flow in the past year.
RPID had negative earnings in each of the past 5 years.
RPID had a negative operating cash flow in each of the past 5 years.
RPID Yearly Net Income VS EBIT VS OCF VS FCFRPID Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

RPID has a worse Return On Assets (-47.76%) than 81.82% of its industry peers.
The Return On Equity of RPID (-62.23%) is worse than 70.91% of its industry peers.
Industry RankSector Rank
ROA -47.76%
ROE -62.23%
ROIC N/A
ROA(3y)-38.74%
ROA(5y)-42.64%
ROE(3y)-47.91%
ROE(5y)-72.28%
ROIC(3y)N/A
ROIC(5y)N/A
RPID Yearly ROA, ROE, ROICRPID Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 1K 2K 3K

1.3 Margins

RPID does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RPID Yearly Profit, Operating, Gross MarginsRPID Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -100 -200 -300

More info and screens

4

2. Health

2.1 Basic Checks

RPID does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, RPID has more shares outstanding
The number of shares outstanding for RPID has been increased compared to 5 years ago.
RPID has a worse debt/assets ratio than last year.
RPID Yearly Shares OutstandingRPID Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
RPID Yearly Total Debt VS Total AssetsRPID Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

RPID has an Altman-Z score of -3.51. This is a bad value and indicates that RPID is not financially healthy and even has some risk of bankruptcy.
RPID's Altman-Z score of -3.51 is on the low side compared to the rest of the industry. RPID is outperformed by 87.27% of its industry peers.
RPID has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
With a decent Debt to Equity ratio value of 0.00, RPID is doing good in the industry, outperforming 74.55% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -3.51
ROIC/WACCN/A
WACC10.58%
RPID Yearly LT Debt VS Equity VS FCFRPID Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M 200M

2.3 Liquidity

A Current Ratio of 4.61 indicates that RPID has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 4.61, RPID is in the better half of the industry, outperforming 72.73% of the companies in the same industry.
A Quick Ratio of 3.46 indicates that RPID has no problem at all paying its short term obligations.
RPID has a Quick ratio of 3.46. This is in the better half of the industry: RPID outperforms 63.64% of its industry peers.
Industry RankSector Rank
Current Ratio 4.61
Quick Ratio 3.46
RPID Yearly Current Assets VS Current LiabilitesRPID Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 14.88% over the past year.
The Revenue has grown by 24.57% in the past year. This is a very strong growth!
Measured over the past years, RPID shows a quite strong growth in Revenue. The Revenue has been growing by 11.18% on average per year.
EPS 1Y (TTM)14.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%16.13%
Revenue 1Y (TTM)24.57%
Revenue growth 3Y6.49%
Revenue growth 5Y11.18%
Sales Q2Q%28.41%

3.2 Future

The Earnings Per Share is expected to grow by 8.33% on average over the next years. This is quite good.
RPID is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 19.18% yearly.
EPS Next Y6.97%
EPS Next 2Y8.33%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year17.83%
Revenue Next 2Y19.18%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
RPID Yearly Revenue VS EstimatesRPID Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 10M 20M 30M 40M
RPID Yearly EPS VS EstimatesRPID Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 -0.5 -1 -1.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for RPID. In the last year negative earnings were reported.
Also next year RPID is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RPID Price Earnings VS Forward Price EarningsRPID Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RPID Per share dataRPID EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1 1.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y8.33%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for RPID!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

RAPID MICRO BIOSYSTEMS INC-A

NASDAQ:RPID (5/30/2025, 8:00:01 PM)

After market: 3.33 0 (0%)

3.33

-0.04 (-1.19%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)05-09 2025-05-09/bmo
Earnings (Next)07-31 2025-07-31/bmo
Inst Owners54.35%
Inst Owner Change19.93%
Ins Owners2.51%
Ins Owner Change21.77%
Market Cap145.95M
Analysts84.44
Price Target8.16 (145.05%)
Short Float %4.07%
Short Ratio5.86
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)3.13%
Min EPS beat(2)0.04%
Max EPS beat(2)6.22%
EPS beat(4)2
Avg EPS beat(4)-0.33%
Min EPS beat(4)-4.8%
Max EPS beat(4)6.22%
EPS beat(8)6
Avg EPS beat(8)4.53%
EPS beat(12)7
Avg EPS beat(12)2.52%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)8.55%
Min Revenue beat(2)3.29%
Max Revenue beat(2)13.82%
Revenue beat(4)4
Avg Revenue beat(4)6.32%
Min Revenue beat(4)0.02%
Max Revenue beat(4)13.82%
Revenue beat(8)8
Avg Revenue beat(8)9.05%
Revenue beat(12)9
Avg Revenue beat(12)3.97%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-12.5%
EPS NY rev (1m)-0.51%
EPS NY rev (3m)-7.07%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0.15%
Revenue NY rev (3m)-0.91%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 5.2
P/FCF N/A
P/OCF N/A
P/B 1.94
P/tB 1.94
EV/EBITDA N/A
EPS(TTM)-1.03
EYN/A
EPS(NY)-0.89
Fwd EYN/A
FCF(TTM)-1.04
FCFYN/A
OCF(TTM)-1.01
OCFYN/A
SpS0.64
BVpS1.72
TBVpS1.72
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -47.76%
ROE -62.23%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-38.74%
ROA(5y)-42.64%
ROE(3y)-47.91%
ROE(5y)-72.28%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.29
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 40.6%
Cap/Sales 4.87%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.61
Quick Ratio 3.46
Altman-Z -3.51
F-Score4
WACC10.58%
ROIC/WACCN/A
Cap/Depr(3y)112.45%
Cap/Depr(5y)118.7%
Cap/Sales(3y)17.47%
Cap/Sales(5y)14.11%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)14.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%16.13%
EPS Next Y6.97%
EPS Next 2Y8.33%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)24.57%
Revenue growth 3Y6.49%
Revenue growth 5Y11.18%
Sales Q2Q%28.41%
Revenue Next Year17.83%
Revenue Next 2Y19.18%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y11.74%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year16.34%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y3%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y2.06%
OCF growth 3YN/A
OCF growth 5YN/A